MedPath

MRIMath's AI-Powered Glioblastoma Tool Receives FDA Clearance

• MRIMath LLC's i 2Contour, an AI-powered tool for glioblastoma mapping and measurement, has received FDA clearance, allowing its marketing to potential customers. • The tool, co-developed by Rowan University and the University of Alabama at Birmingham, aims to improve efficiency and accuracy in tumor contouring, potentially reducing healthcare costs. • i 2Contour uses AI trained on MRI images to delineate tumor boundaries, assess previous scans, and predict tumor growth, enabling earlier detection and response to tumor development. • The technology has garnered interest from universities and hospital systems, with potential to improve patient outcomes in glioblastoma treatment.

MRIMath LLC, a medical technology company co-founded by Rowan University and the University of Alabama at Birmingham, has received FDA clearance for its AI-powered tool, MRIMath i 2Contour, designed for mapping and measuring glioblastoma brain tumors. This clearance allows MRIMath to market the tool to healthcare providers, potentially improving patient outcomes and reducing healthcare costs.

How i 2Contour Works

i 2Contour is a cloud-based cyber tool that utilizes artificial intelligence to enhance the efficiency and accuracy of glioblastoma tumor mapping. Trained on a vast dataset of MRI images, the tool delineates tumor boundaries with pixel-level accuracy. It also assesses previous radiological scans to calculate tumor volume and predict growth trends using statistical methods. According to MRIMath, the device can save physicians hours per imaging study and significantly reduce bottlenecks in contouring, accelerating patient care.

Clinical Significance

Glioblastoma is the most common and deadly primary brain tumor in adults. The ability to accurately and quickly assess tumor characteristics, such as location, volume, and shape, is critical for effective treatment planning. Nidhal C. Bouaynaya, Ph.D., professor at Rowan University and co-founder of MRIMath, noted the challenges in anticipating tumor evolution, stating, "It’s incredibly challenging to anticipate tumor characteristics, such as location, volume and shape, as it evolves. AI is the best system for this level of complexity, as it can analyze vast amounts of data to accurately predict tumor characteristics."

Development and Support

MRIMath, LLC, received support from the Rowan Innovation Venture Fund, the National Institutes of Health Small Business Innovation Research (SBIR) program (Phases I and II), the National Science Foundation’s Innovation Corps, the New Jersey Commission on Science and Technology and the Innovate Alabama award. This support has been crucial in developing and validating the technology. The company reports that universities and hospital systems have already expressed interest in the product.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Ultromics' EchoGo® Amyloidosis Receives FDA Clearance for Cardiac Amyloidosis Detection

Ultromics' EchoGo® Amyloidosis, an AI-based software, has received FDA clearance for early detection of Cardiac Amyloidosis, a frequently underdiagnosed cause of heart failure.
The device, part of the EchoGo® platform, requires only a single echocardiographic clip, reducing the need for extensive clinical information compared to current diagnostic methods.

FDA Approves AI Tool icobrain aria for Detecting ARIA in Alzheimer's Immunotherapy Patients

The FDA has approved icobrain aria, an AI-driven software, to assist in detecting ARIA (Amyloid-Related Imaging Abnormalities) in MRI scans of patients undergoing amyloid immunotherapy.
Clinical studies showed that radiologists using icobrain aria improved their sensitivity in detecting ARIA-E from 71% to 87% and ARIA-H from 69% to 79%.

FDA Clears AI-Driven MRI Tool icobrain aria for Safer Alzheimer's Treatment

The FDA has cleared icobrain aria, the first AI software for detecting and grading amyloid-related imaging abnormalities (ARIA) linked to Alzheimer's therapies.
Clinical studies showed icobrain aria significantly improves radiologists' accuracy in ARIA assessment, enhancing the safety of amyloid-targeting treatments.

icometrix's AI-Powered icobrain aria Receives FDA Clearance for ARIA Detection

icometrix's icobrain aria, an AI-driven MRI solution, has received FDA clearance for detecting amyloid-related imaging abnormalities (ARIA).
The AI software improves the accuracy of ARIA assessments, a potential side effect of amyloid-targeting therapies for Alzheimer's disease.

FDA Clears Icobrain Aria: AI Tool for Enhanced ARIA Detection in Alzheimer's Treatments

The FDA has cleared Icobrain Aria, the first AI software for detecting and grading amyloid-related imaging abnormalities (ARIA) associated with Alzheimer's treatments.
Icobrain Aria uses brain MRI scans to generate a quantitative report, including severity scores for ARIA-edema and ARIA-hemorrhages, integrated into hospital workflows.

FDA Authorizes AI-Driven MRI Solution Icobrain Aria for Safer Alzheimer's Treatment

The FDA has cleared Icometrix's Icobrain Aria, the first AI software for detecting and monitoring amyloid-related imaging abnormalities (ARIA) in Alzheimer's patients.
Icobrain Aria improves the accuracy of ARIA assessments by radiologists, enhancing the safety of amyloid-targeting therapies for Alzheimer's disease.

Recursion's REC-1245 Receives FDA Clearance for Phase 1/2 Cancer Trial

Recursion's REC-1245, a novel chemical entity, has been cleared by the FDA for a Phase 1/2 clinical trial targeting solid tumors and lymphoma.
The trial, set to begin in Q4 2024, will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and potential efficacy of REC-1245 as a monotherapy.

BridgeBio's BBP-812 Receives FDA RMAT Designation for Canavan Disease Gene Therapy

BridgeBio Pharma's BBP-812, a gene therapy for Canavan disease, has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA.
The RMAT designation is based on positive Phase 1/2 trial data, showing functional improvements in treated patients and reduced N-acetylaspartate (NAA) levels.

FDA Grants Breakthrough Device Designation to Roche's Elecsys pTau217 Assay for Alzheimer's Diagnosis

The FDA has granted Breakthrough Device Designation to Roche's Elecsys pTau217 assay, a blood test aiding in identifying amyloid pathology in individuals.
This test, developed with Eli Lilly, aims to provide timely and accurate Alzheimer's diagnoses, potentially mitigating the disease's impact and facilitating clinical trial participation.

Recursion's AI-Discovered Cancer Treatment REC-1245 Receives FDA Clearance for Phase 1/2 Trial

Recursion's REC-1245, an AI-discovered drug for biomarker-enriched solid tumors and lymphoma, has received FDA clearance for a Phase 1/2 clinical trial.
The trial will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and potential efficacy of REC-1245 as a monotherapy.

Reference News

[1]
Rowan-based startup receives FDA clearance for medical technology
today.rowan.edu · Nov 12, 2024

MRIMath, LLC's AI-powered tool, MRIMath i2Contour, co-developed by Rowan University and the University of Alabama at Bir...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy